TG Therapeutics Inc (TGTX)

[postmeridiem]

TGTX implied all the B-cell depleting drugs work pretty much the same. They may have an advantage in fewer adverse reactions at the infusion site.

TGTX said their main advantages are speed of infusion and lower cost (they said they can see cutting the cost from $80,000 to $40,000). They expect to take a large share of the existing market with those advantages, if they get FDA approval.